This clinical trial is focused on studying the treatment of non-muscle invasive bladder cancer, a type of bladder cancer that has not spread into the muscle layer of the bladder. The study will evaluate the effectiveness and safety of a combination therapy using Durvalumab and Bacillus Calmette-Guérin (BCG), compared to the standard treatment of BCG alone. Durvalumab is a medication that helps the immune system fight cancer, while BCG is a vaccine that is used to treat bladder cancer by stimulating the immune system.

The purpose of the study is to assess how well the combination of Durvalumab and BCG works in preventing the return of cancer, known as disease-free survival. Participants in the study will receive either the combination therapy or BCG alone. The study will last for up to 12 months, during which participants will be monitored regularly to evaluate the treatment’s effectiveness and any side effects. The study aims to provide more information on whether adding Durvalumab to the standard BCG treatment can improve outcomes for patients with this type of bladder cancer.

Throughout the study, participants will undergo regular check-ups and assessments to track their health and the progress of the treatment. The study will also look at other important outcomes, such as the time it takes for the cancer to become muscle-invasive or spread, and the overall survival rate of participants. The information gathered from this study will help determine if the combination of Durvalumab and BCG is a more effective treatment option for patients with non-muscle invasive bladder cancer.